New AURKA inhibitors, such as CD532 and PHA-680626, have shown a greater effect than alisertib on MYCN protein stability, and decreased the viability of NB cells in xenograft models, but they remain to be studied in NB patients [45,46]. Here, MYCN is linked to neuroblastoma.